<p><strong>Hims &amp; Hers Health Inc.</strong> HIMS 在周二盘前暴跌 13.1%，此前这家数字健康公司在周一公布的第二季度收入未能达到华尔街的预期。</p>
<p>热门投资机会</p>
<h2>Hims &amp; Hers 第二季度销售未达预期，利润超出预期，展望增长</h2>
<p>该公司报告第二季度收入为 2.782 亿美元，低于分析师预测的 2.802 亿美元。净收入为 1170 万美元，或每股 0.05 美元，超出预期，并较去年同期的 780 万美元有显著改善。然而，收入未达预期导致周一股价回落。</p>
<p>尽管出现短缺，管理层仍然保持积极的增长前景，强调未来的新机会，特别是在减肥领域。</p>
<p>首席执行官 <strong>Andrew Dudum</strong> 在周一的财报电话会议上保持乐观，称这是 “一个创新和增长的激动人心的时期”。他强调了 Hims &amp; Hers 最近进入 GLP-1 减肥药市场的扩展，这一举措被视为对 <strong>诺和诺德</strong>NVO 和 <strong>礼来</strong>LLY 等传统玩家动能减弱的战略反击。</p>
<h2><strong>Hims 在 GLP-1 竞争对手面临定价和安全压力时获益</strong></h2>
<p>在 7 月份，Hims 的股票在宣布计划以更可接受的价格提供 GLP-1 药物的复合版本后飙升至接近历史最高点。这一势头与诺和诺德股票的近期疲软相吻合，一些分析师将其归因于对患者留存率和与 Wegovy 长期使用相关的警告标签的担忧。</p>
<p>随着诺和诺德和礼来在定价和副作用方面面临越来越多的审查，Hims 正在利用其远程医疗平台和垂直整合的供应链，将自己定位为一个更具可扩展性和消费者友好的替代品。Futurum Equities 的首席市场策略师 <strong>Shay Bolor</strong> 表示，如果诺和诺德 “采纳 Hims 的模式”，可能会减轻近期的股票波动。</p>
<p>尽管第二季度收入未达预期，Hims 在减肥类别中的强劲用户增长和竞争性定价表明，该公司仍可能在长期内具有上行空间，尤其是在体重管理持续推动数字健康平台需求的背景下。</p>
<p><strong>Benzinga Edge 股票排名</strong> 显示，Hims &amp; Hers Health 在长期、中期和短期内均表现出强劲的价格趋势。其动量排名为 98.06，而增长排名则强劲，达到 98.98；其他指标的详细信息可在此处查看。</p>
<ul>
<li><strong>Hims &amp; Hers 股票可能会因空头卖家感到压力而飞升至迷因股票的名声</strong></li>
</ul>
<p><em>图片来源于 Shutterstock</em></p>

HIMS

<p>Hims & Hers Health Inc. 在盘前交易中股价暴跌 13.1%，原因是其第二季度收入为 2.782 亿美元，未能达到分析师预期的 2.802 亿美元。尽管净收入为 1170 万美元，超过了预期，但收入的短缺导致股价回落。首席执行官安德鲁·杜杜姆对增长保持乐观，特别是在减肥领域，因为公司正在扩展到 GLP-1 药物市场。分析师建议，尽管最近收入未达预期，但 Hims 的竞争性定价和用户增长可能在长期内带来上行空间</p>

<p><strong>Hims &amp; Hers Health Inc.</strong> HIMS plunged 13.1% in Tuesday pre-market after the digital health company reported second-quarter revenue on Monday that missed Wall Street expectations.</p>
<div class="lb-trans"><p><strong>Hims &amp; Hers Health Inc.</strong> HIMS 在周二盘前暴跌 13.1%，此前这家数字健康公司在周一公布的第二季度收入未能达到华尔街的预期。</p>
</div><p>Trending Investment Opportunities</p>
<div class="lb-trans"><p>热门投资机会</p>
</div><h2>Hims &amp; Hers Misses Q2 Sales, Beats On Profit, Eyes Growth</h2>
<div class="lb-trans"><h2>Hims &amp; Hers 第二季度销售未达预期，利润超出预期，展望增长</h2>
</div><p>The company reported $278.2 million in Q2 revenue, falling short of analyst forecasts of $280.2 million. Net income came in at $11.7 million, or $0.05 per share, topping estimates and marking a notable improvement from the $7.8 million reported a year earlier. However, the revenue miss triggered a pullback in the stock on Monday.</p>
<div class="lb-trans"><p>该公司报告第二季度收入为 2.782 亿美元，低于分析师预测的 2.802 亿美元。净收入为 1170 万美元，或每股 0.05 美元，超出预期，并较去年同期的 780 万美元有显著改善。然而，收入未达预期导致周一股价回落。</p>
</div><p>Despite the shortfall, management maintained a positive growth outlook, highlighting new opportunities ahead, especially in the weight loss space.</p>
<div class="lb-trans"><p>尽管出现短缺，管理层仍然保持积极的增长前景，强调未来的新机会，特别是在减肥领域。</p>
</div><p>CEO <strong>Andrew Dudum</strong> remained upbeat, calling it “an exciting period of innovation and growth” during Monday’s earnings call. He emphasized Hims &amp; Hers’ recent expansion into the GLP-1 weight loss drug market, a move seen as a strategic counter to flagging momentum among legacy players like <strong>Novo Nordisk</strong> NVO and <strong>Eli Lilly</strong> LLY.</p>
<div class="lb-trans"><p>首席执行官 <strong>Andrew Dudum</strong> 在周一的财报电话会议上保持乐观，称这是 “一个创新和增长的激动人心的时期”。他强调了 Hims &amp; Hers 最近进入 GLP-1 减肥药市场的扩展，这一举措被视为对 <strong>诺和诺德</strong>NVO 和 <strong>礼来</strong>LLY 等传统玩家动能减弱的战略反击。</p>
</div><h2><strong>Hims gains as GLP-1 rivals face pricing, safety heat</strong></h2>
<div class="lb-trans"><h2><strong>Hims 在 GLP-1 竞争对手面临定价和安全压力时获益</strong></h2>
</div><p>In July, Hims stock had surged to near all-time highs after announcing plans to offer compounded versions of GLP-1 drugs—popularly used in Wegovy and Ozempic—at a more accessible price point. That momentum coincided with recent weakness in Novo Nordisk's stock, which some analysts attributed to concerns about patient retention and warning labels related to Wegovy's long-term use.</p>
<div class="lb-trans"><p>在 7 月份，Hims 的股票在宣布计划以更可接受的价格提供 GLP-1 药物的复合版本后飙升至接近历史最高点。这一势头与诺和诺德股票的近期疲软相吻合，一些分析师将其归因于对患者留存率和与 Wegovy 长期使用相关的警告标签的担忧。</p>
</div><p>As Novo Nordisk and Eli Lilly face increasing scrutiny over pricing and side effects, Hims is leveraging its telehealth platform and vertically integrated supply chain to position itself as a more scalable and consumer-friendly alternative. <strong>Shay Bolor</strong>, the chief market strategist at Futurum Equities stated that if Novo had &#34;embraced Hims' model,&#34; it might have mitigated recent stock volatility.</p>
<div class="lb-trans"><p>随着诺和诺德和礼来在定价和副作用方面面临越来越多的审查，Hims 正在利用其远程医疗平台和垂直整合的供应链，将自己定位为一个更具可扩展性和消费者友好的替代品。Futurum Equities 的首席市场策略师 <strong>Shay Bolor</strong> 表示，如果诺和诺德 “采纳 Hims 的模式”，可能会减轻近期的股票波动。</p>
</div><p>Despite the Q2 revenue miss, Hims’ strong user growth and competitive pricing in the weight loss category suggest the company may still hold long-term upside—especially as weight management continues to drive demand across digital health platforms.</p>
<div class="lb-trans"><p>尽管第二季度收入未达预期，Hims 在减肥类别中的强劲用户增长和竞争性定价表明，该公司仍可能在长期内具有上行空间，尤其是在体重管理持续推动数字健康平台需求的背景下。</p>
</div><p><strong>Benzinga Edge Stock Rankings</strong> shows that Hims &amp; Hers Health had a strong price trend over the long, medium and short term. Its momentum ranking was 98.06, whereas its growth ranking was strong at 98.98; the details of other metrics are available here.</p>
<div class="lb-trans"><p><strong>Benzinga Edge 股票排名</strong> 显示，Hims &amp; Hers Health 在长期、中期和短期内均表现出强劲的价格趋势。其动量排名为 98.06，而增长排名则强劲，达到 98.98；其他指标的详细信息可在此处查看。</p>
</div><ul>
<li><strong>Hims &amp; Hers Stock Could Rocket To Meme Stock Fame — If Short Sellers Feel The Squeeze</strong></li>
</ul>
<div class="lb-trans"><ul>
<li><strong>Hims &amp; Hers 股票可能会因空头卖家感到压力而飞升至迷因股票的名声</strong></li>
</ul>
</div><p><em>Image via Shutterstock</em></p>
<div class="lb-trans"><p><em>图片来源于 Shutterstock</em></p>
</div>

Hims & Hers Health 的股票在周二盘前暴跌超过 13%：究竟发生了什么情况？